Opinion|Videos|November 18, 2026

What Positive OrigAMI-5 Results Would Mean

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, reflects on what positive results from OrigAMI-5 could mean for the first-line treatment paradigm in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, reflects on what positive results from OrigAMI-5 could mean for the first-line treatment paradigm in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). He anticipates that 2027 and 2028 could bring as many as 3 positive first-line phase 3 trials in this space: OrigAMI-5, establishing carboplatin plus amivantamab plus pembrolizumab as an active combination; a study of ficerafusp alfa plus pembrolizumab in patients with a PD-L1 combined positive score (CPS) of 1 or higher; and a study of petosemtamab plus pembrolizumab in the same CPS-positive population. Dr. Swiecicki says the ultimate impact will depend on toxicity data, subgroup analyses, and whether a predictive biomarker emerges. He calls this a meaningful advance, noting it has been roughly a decade since a new therapeutic meaningfully improved outcome in this underrecognized patient population.


Related to this article